Novo Nordisk has abandoned another GLP-1/GIP co-agonist and CB1 receptor as part of a significant pipeline clearout that ...

The Department of Health and Human Services has announced a plan to end mRNA vaccine work funded by the Biomedical Advanced ...

Orchestra BioMed reported that it has secured over $111 million in financing through a series of transactions and ...

As part of a "strategic alignment" of its pipeline, BioNTech is laying off 90 workers in R&D and corporate roles across two sites in Maryland and Massachusetts, a spokesperson told Fierce. | As part ...

Alcon is building out its portfolio of lens implants, with a $1.5 billion deal to acquire the flagging Staar Surgical and its ...

A phase 2b trial of HMNC Brain Health’s depression drug candidate has missed its primary endpoint. But while the ex-Sanofi molecule failed to move the needle in the overrall population, results in ...

Imunon has confirmed the deprioritization of its COVID-19 vaccine program. With the company’s cash reserves falling below $5 ...

Pfizer's beleaguered obesity strategy has hit another setback as the pharma jettisoned its third and final GLP-1 agonist, ...

BioMarin Pharmaceutical is continuing to slim down its pipeline, this time ending work on a preclinical phenylketonuria (PKU) ...

Vertex Pharmaceuticals has hit a snag in its efforts to follow up non-opioid pain reliever Journavx (suzetrigine). | Vertex ...

The FDA formally kicked off its quinquennial process to reauthorize the federal user fee legislation that helps fund its ...

A Senate committee has rejected President Donald Trump’s efforts to gouge funding for the National Institutes of Health (NIH) ...